Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedAug 23, 2026
DataAggregated Company Financials
Companies20
  • 7D2.0%
  • 3M5.4%
  • 1Y-14.0%
  • YTD-7.7%

The Healthcare industry is up 2.0% in the last week, with Novo Nordisk up 2.1%. In the past year, the industry is down 14%. Looking forward, earnings are forecast to grow by 4.5% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 24 Aug 2026DKK 1.8tDKK 468.0bDKK 137.2b23.3x13.1x3.8x
Wed, 22 Jul 2026DKK 1.9tDKK 469.4bDKK 147.2b20x12.7x4x
Fri, 19 Jun 2026DKK 1.6tDKK 469.1bDKK 147.1b19.4x11.2x3.5x
Sun, 17 May 2026DKK 1.7tDKK 468.7bDKK 147.0b20.3x11.8x3.7x
Tue, 14 Apr 2026DKK 1.5tDKK 447.2bDKK 129.9b18.1x11.3x3.3x
Thu, 12 Mar 2026DKK 1.5tDKK 448.3bDKK 131.1b17.4x11.6x3.4x
Sat, 07 Feb 2026DKK 1.8tDKK 448.2bDKK 134.5b16.7x13.1x3.9x
Mon, 05 Jan 2026DKK 2.0tDKK 453.8bDKK 136.9b17x14.3x4.3x
Wed, 03 Dec 2025DKK 1.9tDKK 454.1bDKK 137.0b17.3x13.7x4.1x
Fri, 31 Oct 2025DKK 1.9tDKK 447.9bDKK 141.8b17.4x13.6x4.3x
Sun, 28 Sep 2025DKK 2.0tDKK 447.4bDKK 141.7b18x14.3x4.5x
Tue, 26 Aug 2025DKK 2.1tDKK 447.6bDKK 141.8b24.5x14.9x4.7x
Thu, 24 Jul 2025DKK 2.4tDKK 423.0bDKK 124.4b30.1x19.5x5.7x
Sat, 21 Jun 2025DKK 2.6tDKK 423.5bDKK 124.6b30.4x20.6x6.1x
Mon, 19 May 2025DKK 2.4tDKK 424.4bDKK 125.1b23.5x18.8x5.5x
Wed, 16 Apr 2025DKK 2.3tDKK 409.3bDKK 121.3b22x19.3x5.7x
Fri, 14 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.7x23.3x6.9x
Sun, 09 Feb 2025DKK 3.3tDKK 408.3bDKK 118.3b28.7x28.1x8.2x
Tue, 07 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.7x29.5x8.5x
Thu, 05 Dec 2024DKK 4.0tDKK 387.3bDKK 111.3b31.6x36.1x10.4x
Sat, 02 Nov 2024DKK 4.0tDKK 372.2bDKK 107.2b34.5x37.1x10.7x
Mon, 30 Sep 2024DKK 4.1tDKK 371.9bDKK 107.1b36.5x38.4x11.1x
Wed, 28 Aug 2024DKK 4.6tDKK 371.7bDKK 107.1b33.1x43.3x12.5x
Fri, 26 Jul 2024DKK 4.5tDKK 355.4bDKK 106.3b35.7x42.4x12.7x
Sun, 23 Jun 2024DKK 4.9tDKK 355.4bDKK 106.2b34.5x46.6x13.9x
Tue, 21 May 2024DKK 4.6tDKK 355.3bDKK 106.2b37.8x43.2x12.9x
Thu, 18 Apr 2024DKK 4.5tDKK 341.3bDKK 99.6b33.9x44.7x13x
Sat, 16 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.3x46.5x13.6x
Mon, 12 Feb 2024DKK 4.3tDKK 340.5bDKK 98.6b33.1x43.3x12.6x
Wed, 10 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b34.1x41.7x11.7x
Fri, 08 Dec 2023DKK 3.5tDKK 320.5bDKK 90.0b33.1x38.7x10.9x
Sun, 05 Nov 2023DKK 3.5tDKK 318.7bDKK 90.3b29.1x39.2x11.1x
Tue, 03 Oct 2023DKK 3.4tDKK 305.6bDKK 82.2b32.8x41.4x11.1x
Thu, 31 Aug 2023DKK 3.4tDKK 305.2bDKK 82.1b35.9x41.6x11.2x
Price to Earnings Ratio

41.6x


Total Market Cap: DKK 3.4tTotal Earnings: DKK 82.1bTotal Revenue: DKK 305.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 28x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 13.1x which is lower than its 3-year average PE of 28.0x.
  • The 3-year average PS ratio of 8.1x is higher than the industry's current PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 19% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market0.75%
Healthcare2.02%
Biotech5.85%
Healthtech5.82%
Life Sciences5.29%
Pharma1.81%
Medical Equipment0.14%
Healthcare Services-0.33%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.8x.
    • Analysts are expecting annual earnings growth of 18.1%, which is higher than its past year's earnings growth of 9.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Pharma industry is expected to see its earnings growth to stay flat over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 300.852.1%
+DKK 27.2b		-17.3%PE11.4x
GMAB GenmabDKK 2.15k6.1%
+DKK 7.4b		37.0%PE25.5x
COLO B ColoplastDKK 438.602.4%
+DKK 2.2b		-28.8%PE35.7x
BAVA Bavarian NordicDKK 209.4012.6%
+DKK 1.7b		-12.3%PE10.3x
CHEMM ChemoMetecDKK 487.405.2%
+DKK 421.1m		-7.4%PE47.9x

Latest News

GUBRA
DKK 391.80
Gubra
7D
5.4%
1Y
5.0%
Analysis Article • 19h

Earnings Beat: Gubra A/S (CPH:GUBRA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Gubra A/S ( CPH:GUBRA ) missed earnings with its latest half-yearly results, disappointing overly-optimistic...
BAVA
DKK 209.40
Bavarian Nordic
7D
12.6%
1Y
-12.3%
DEMANT
DKK 287.00
Demant
7D
-3.5%
1Y
11.8%
HLUN B
DKK 41.04
H. Lundbeck
7D
-3.5%
1Y
2.9%
Narrative Update • Aug 23

HLUN B: Advancing Neuroscience Pipeline Will Support Future Upside Potential

Analysts have raised their fair value estimate for H. Lundbeck from DKK 47.21 to DKK 48.73.
ALK B
DKK 216.00
ALK-Abelló
7D
-1.2%
1Y
3.3%
GMAB
DKK 2,151.00
Genmab
7D
6.1%
1Y
37.0%
Narrative Update • Aug 21

GMAB: Upcoming Oncology Readouts Will Support Commercial Transition And Offset Patent Cliff

Genmab's updated analyst price target has shifted modestly to DKK 2,930, as analysts factor in higher assumed revenue growth, a slightly lower profit margin profile, a higher discount rate and a lower future P/E multiple, supported by recent research citing confidence in Epkinly, rinatabart sesutecan and petosemtamab, stronger Q2 results, raised 2026 guidance and inclusion on a conviction list. Analyst Commentary Recent Street research on Genmab points to a cluster of supportive views, with several bullish analysts lifting price targets and upgrading ratings following Q2 results, updated 2026 guidance and progress across key oncology assets.
NOVO B
DKK 300.85
Novo Nordisk
7D
2.1%
1Y
-17.3%
Narrative Update • Aug 21

NOVO B: Future Returns Will Rely On Obesity Pills Versus Pipeline Setbacks

Analysts have trimmed their price target for Novo Nordisk to DKK 309.73 from DKK 316.91. This reflects updated assumptions that incorporate a slightly higher discount rate, a revised revenue growth outlook, modestly stronger profit margins, and a lower future P/E multiple.
COLO B
DKK 438.60
Coloplast
7D
2.4%
1Y
-28.8%
Analysis Article • Aug 21

Coloplast A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

The quarterly results for Coloplast A/S ( CPH:COLO B ) were released last week, making it a good time to revisit its...
ZEAL
DKK 321.20
Zealand Pharma
7D
0%
1Y
-22.9%
Analysis Article • Aug 18

Earnings Beat: Zealand Pharma A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of second-quarter numbers that could potentially...
AMBU B
DKK 76.80
Ambu
7D
0.3%
1Y
-24.6%
Narrative Update • Aug 15

AMBU B: Rising Competitive Pressure Will Drive More Cautious Share Performance

Analysts have raised their fair value estimate for Ambu to DKK 61 from DKK 58, while also reflecting slightly different assumptions for growth, margins and future P/E following recent research that highlights rising competitive pressure and a more cautious near term outlook. What’s in the News for Ambu Analysts revised their fair value estimate for Ambu to DKK 61 from DKK 58, reflecting updated assumptions on growth, margins and future P/E.
CHEMM
DKK 487.40
ChemoMetec
7D
5.2%
1Y
-7.4%
EMBLA
DKK 30.00
Embla Medical hf
7D
0.5%
1Y
-6.3%
Analysis Article • Jul 24

Embla Medical hf. Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting Next

Embla Medical hf. ( CPH:EMBLA ) last week reported its latest second-quarter results, which makes it a good time for...
SMSMED
DKK 2.98
Scandinavian Medical Solutions
7D
-0.3%
1Y
-30.2%
STRAP
DKK 700.00
Strategic Partners
7D
-6.0%
1Y
-30.0%